NovoCure reported a quarterly loss of $0.13 per share, improving versus the Zacks Consensus loss of $0.30 and versus a year-ago loss of $0.36. The narrower loss suggests better-than-expected performance, though still remains unprofitable.
NovoCure reported a quarterly loss of $0.13 per share, improving versus the Zacks Consensus loss of $0.30 and versus a year-ago loss of $0.36. The narrower loss suggests better-than-expected performance, though still remains unprofitable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
